1. Home
  2. IMUX vs MCHX Comparison

IMUX vs MCHX Comparison

Compare IMUX & MCHX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • IMUX
  • MCHX
  • Stock Information
  • Founded
  • IMUX 2016
  • MCHX 2003
  • Country
  • IMUX United States
  • MCHX United States
  • Employees
  • IMUX N/A
  • MCHX N/A
  • Industry
  • IMUX Biotechnology: Pharmaceutical Preparations
  • MCHX Business Services
  • Sector
  • IMUX Health Care
  • MCHX Consumer Discretionary
  • Exchange
  • IMUX Nasdaq
  • MCHX Nasdaq
  • Market Cap
  • IMUX 86.3M
  • MCHX 84.3M
  • IPO Year
  • IMUX N/A
  • MCHX 2004
  • Fundamental
  • Price
  • IMUX $0.98
  • MCHX $1.94
  • Analyst Decision
  • IMUX Strong Buy
  • MCHX
  • Analyst Count
  • IMUX 6
  • MCHX 0
  • Target Price
  • IMUX $12.67
  • MCHX N/A
  • AVG Volume (30 Days)
  • IMUX 1.0M
  • MCHX 26.5K
  • Earning Date
  • IMUX 02-20-2025
  • MCHX 03-13-2025
  • Dividend Yield
  • IMUX N/A
  • MCHX N/A
  • EPS Growth
  • IMUX N/A
  • MCHX N/A
  • EPS
  • IMUX N/A
  • MCHX N/A
  • Revenue
  • IMUX N/A
  • MCHX $48,594,000.00
  • Revenue This Year
  • IMUX N/A
  • MCHX N/A
  • Revenue Next Year
  • IMUX N/A
  • MCHX $4.63
  • P/E Ratio
  • IMUX N/A
  • MCHX N/A
  • Revenue Growth
  • IMUX N/A
  • MCHX N/A
  • 52 Week Low
  • IMUX $0.92
  • MCHX $1.11
  • 52 Week High
  • IMUX $2.11
  • MCHX $2.40
  • Technical
  • Relative Strength Index (RSI)
  • IMUX 44.34
  • MCHX 46.43
  • Support Level
  • IMUX $0.94
  • MCHX $1.92
  • Resistance Level
  • IMUX $1.02
  • MCHX $2.06
  • Average True Range (ATR)
  • IMUX 0.06
  • MCHX 0.08
  • MACD
  • IMUX 0.00
  • MCHX 0.00
  • Stochastic Oscillator
  • IMUX 44.96
  • MCHX 53.57

About IMUX Immunic Inc.

Immunic Inc is a clinical-stage biopharmaceutical company developing a pipeline of selective oral immunology therapies aimed at treating chronic inflammatory and autoimmune diseases, including ulcerative colitis, Crohn's disease, relapsing-remitting multiple sclerosis, and psoriasis. The company is developing small molecule products, which include IMU-838, which is a selective immune modulator that inhibits the intracellular metabolism of activated immune cells by blocking the enzyme DHODH; IMU-935 is an inverse agonist of RORyt, and IMU-856 targets the restoration of the intestinal barrier function.

About MCHX Marchex Inc. Class B

Marchex Inc is a conversational analytics and solutions company that helps businesses connect, drive, measure, convert callers into customers, and connect the voice of the customer to their business. It delivers data insights and incorporates artificial intelligence (AI)-powered functionality that drives insights and solutions to help companies find, engage, and support their customers across voice and text-based communication channels. The group enables sales and marketing teams to deliver the buying experiences that today's customers expect. The company generates the majority of its revenues from core analytics and solutions services. The company operates in the United States, Canada, and other countries.

Share on Social Networks: